Posted by Michael Wonder on 03 Oct 2017
Advanced Accelerator Applications announces European approval of Lutetium (177Lu) oxodotreotide (Lutathera) for gastro-enteropancreatic neuroendocrine tumours
29 September 2017 - Completes first theragnostic radiopharmaceutical pairing in oncology.
Advanced Accelerator Applications today announced that the European Commission has approved the marketing authorisation of lutetium (177Lu) oxodotreotide (Lutathera) for “the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults.”
This approval allows for the marketing of lutetium (177Lu) oxodotreotide (Lutathera) in all 28 European Union member states, as well as Iceland, Norway and Liechtenstein.
